Polo-like Kinase 1 Protects Intestinal Epithelial Cells from Apoptosis During Sepsis via the Nuclear Factor-kB Pathway

0
0
0

Polo-like Kinase 1 Protects Intestinal Epithelial Cells from Apoptosis During Sepsis via the Nuclear Factor-kB Pathway

Sepsis is a deadly condition where the body’s fight against infection spirals out of control, damaging organs like the lungs, kidneys, and even the gut. The gut—often called the “motor of sepsis”—relies on a delicate balance of epithelial cell growth and death to maintain its protective barrier. When sepsis strikes, too many of these cells die (a process called apoptosis), breaking down the barrier and letting harmful bacteria and toxins leak into the bloodstream—worsening sepsis. But what drives this cell death? A 2020 study from researchers at Wannan Medical College’s Yijishan Hospital reveals a critical molecular pathway: the interaction between polo-like kinase 1 (PLK1) and nuclear factor-kB (NF-kB).

What the Researchers Did

To unlock sepsis’s impact on the gut, the team combined lab experiments with clinical data:

  • Lab Models: They used HT-29 cells—a human colorectal cancer cell line that mimics normal intestinal epithelial cells—to create a sepsis-like environment with lipopolysaccharide (LPS), a bacterial toxin that triggers inflammation. They measured NF-kB activity (via proteins like IkB-α, which keeps NF-kB “off,” and NF-kB p65, which moves to the nucleus when active) and apoptosis (via pro-caspase-3, a marker of cell death).
  • Inhibitor Tests: To study NF-kB’s role, they pre-treated cells with pyrrolidine dithiocarbamic acid (PDTC), an NF-kB inhibitor, before adding LPS. To link PLK1 (a cell cycle kinase) to NF-kB, they used BI2536, a PLK1 inhibitor.
  • Clinical Samples: They analyzed 21 pairs of intestinal tissue from sepsis patients: necrotic tissue (damaged by sepsis) and normal tissue from surgical margins.

Key Findings

The results painted a clear picture of how sepsis harms the gut:

  1. LPS Activates NF-kB: LPS treatment reduced IkB-α (a sign NF-kB was “on”) and increased NF-kB p65’s movement to the nucleus—proof the pathway was active.
  2. NF-kB Drives Apoptosis: When the team blocked NF-kB with PDTC, pro-caspase-3 levels stayed high (fewer cells died). This meant NF-kB activation promoted cell death in sepsis.
  3. PLK1 Controls NF-kB: The team had previously found LPS lowers PLK1 levels. Now, they saw that blocking PLK1 with BI2536 made NF-kB more active—showing PLK1 normally keeps NF-kB in check.
  4. Clinical Confirmation: Necrotic intestinal tissue from sepsis patients had less PLK1, more active NF-kB, and higher apoptosis markers (pro-caspase-3 and pro-caspase-9) than normal tissue.

Why This Matters

NF-kB is best known for regulating inflammation—turning on genes for proteins like TNF-α and IL-6 that fight infection. But its role in cell death is dual: it can both prevent and promote apoptosis, depending on the situation. In this study, sepsis tipped the balance toward death: NF-kB activation pushed intestinal cells to die.

PLK1, meanwhile, acts as a “brake” on NF-kB. When sepsis lowers PLK1 levels, NF-kB turns on—and apoptosis follows. This means the PLK1-NF-kB pathway is a critical driver of intestinal barrier failure in sepsis.

The Takeaway

For patients, this study points to a potential new target for treating sepsis-related gut damage: preserving PLK1 or inhibiting NF-kB could protect intestinal epithelial cells, keeping the barrier intact and slowing sepsis’s progression.

This research was conducted by Ying-Ya Cao, Zhen Wang, Lin-Ming Lu, Zeng-Xiang Xu, Jia-Jia Li, Xiao-Gan Jiang, and Wei-Hua Lu from the Department of Intensive Care Unit and Department of Pathology at Yijishan Hospital, First Affiliated Hospital of Wannan Medical College, Wuhu, China. It was published in the Chinese Medical Journal in 2020.

doi.org/10.1097/CM9.0000000000000780

Was this helpful?

0 / 0